Humalog and Empliciti drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Humalog (insulin lispro recombinant) and Empliciti (elotuzumab). Common drug interactions include thrombosis among females and diarrhoea among males.

The phase IV clinical study analyzes what interactions people have when they take Humalog and Empliciti. It is created by eHealthMe based on reports of 23 people who take the same drugs from the FDA, and is updated regularly.

What is Humalog?

Humalog has active ingredients of insulin lispro recombinant. It is often used in diabetes. eHealthMe is studying from 137,127 Humalog users. Check the latest studies of Humalog.

What is Empliciti?

Empliciti has active ingredients of elotuzumab. eHealthMe is studying from 2,545 Empliciti users. Check the latest studies of Empliciti.

On Jul, 15, 2026

23 people who take Humalog and Empliciti together, and have interactions are studied.

Humalog and Empliciti drug interactions.

What are the common drug interactions of Humalog and Empliciti, by gender? *:

female:

Thrombosis (formation of a blood clot inside a blood vessel)
Blood glucose increased
Blood pressure decreased
Gastrointestinal inflammation (inflammation of stomach and intestine)
Back pain
Blood cholesterol increased
Hypertension (high blood pressure)
Musculoskeletal disorder (disease of the body's muscles, joints, tendons, ligaments and nerves)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Plasma cell myeloma (cancer that begins in plasma cells)

male:

Diarrhoea
Fatigue (feeling of tiredness)
Hypersomnia (excessive daytime sleepiness (eds))
Infection
Lethargy (tiredness)
Localised infection (infection at the single location)
Plasma cell myeloma (cancer that begins in plasma cells)
Pulmonary hypertension (increase in blood pressure in the lung artery)
Renal disorder (kidney disease)
Urinary tract infection

What are the common drug interactions of Humalog and Empliciti, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Plasma cell myeloma (cancer that begins in plasma cells)
Pneumonia
Thrombocytopenia (decrease of platelets in blood)

60+:

Blood pressure decreased
Diarrhoea
Hypersomnia (excessive daytime sleepiness (eds))
Infection
Lethargy (tiredness)
Localised infection (infection at the single location)
Platelet count decreased
Pulmonary hypertension (increase in blood pressure in the lung artery)
Skin cancer
Gastrointestinal inflammation (inflammation of stomach and intestine)

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 22 people, 95.65%

* Approximation only. Some reports may have incomplete information.

Do you take Humalog and Empliciti?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously